![Contrastive Studies of Cytarabine/Daunorubicin Dual-Loaded Liposomes Prepared by pH Gradient and Cu2+ Gradient Method | SpringerLink Contrastive Studies of Cytarabine/Daunorubicin Dual-Loaded Liposomes Prepared by pH Gradient and Cu2+ Gradient Method | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1208%2Fs12249-020-01867-x/MediaObjects/12249_2020_1867_Fig2_HTML.png)
Contrastive Studies of Cytarabine/Daunorubicin Dual-Loaded Liposomes Prepared by pH Gradient and Cu2+ Gradient Method | SpringerLink
![Cureus | Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review | Article Cureus | Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review | Article](https://assets.cureus.com/uploads/figure/file/508805/article_river_a05424d071e211edaddcf3290a438177-FIGURE-1.png)
Cureus | Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review | Article
![Chemotherapy dosing schedule. The schedule for ARA-C (200 mg/m 2 /d),... | Download Scientific Diagram Chemotherapy dosing schedule. The schedule for ARA-C (200 mg/m 2 /d),... | Download Scientific Diagram](https://www.researchgate.net/publication/8451537/figure/fig1/AS:341207357116424@1458361581940/Chemotherapy-dosing-schedule-The-schedule-for-ARA-C-200-mg-m-2-d-daunorubicin-50.png)
Chemotherapy dosing schedule. The schedule for ARA-C (200 mg/m 2 /d),... | Download Scientific Diagram
![IJMS | Free Full-Text | Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine IJMS | Free Full-Text | Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine](https://www.mdpi.com/ijms/ijms-22-02337/article_deploy/html/images/ijms-22-02337-g001-550.jpg)
IJMS | Free Full-Text | Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
![MRC-AML11 protocol flow chart. DAT 3 10: daunorubicin 50 mg/m 2 slow... | Download Scientific Diagram MRC-AML11 protocol flow chart. DAT 3 10: daunorubicin 50 mg/m 2 slow... | Download Scientific Diagram](https://www.researchgate.net/publication/11824570/figure/fig1/AS:394527396384768@1471074069100/MRC-AML11-protocol-flow-chart-DAT-3-10-daunorubicin-50-mg-m-2-slow-intravenous-IV.png)
MRC-AML11 protocol flow chart. DAT 3 10: daunorubicin 50 mg/m 2 slow... | Download Scientific Diagram
![Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-07701-8/MediaObjects/12885_2020_7701_Fig3_HTML.png)
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
![Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial - The Lancet Haematology Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial - The Lancet Haematology](https://www.thelancet.com/cms/attachment/a29bdb5a-d820-4340-a9ee-aad2751e2b3d/gr1_lrg.gif)
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial - The Lancet Haematology
![RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia | Pharmacogenomics RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia | Pharmacogenomics](https://www.futuremedicine.com/cms/10.2217/pgs.15.44/asset/images/medium/figure1.gif)
RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia | Pharmacogenomics
![A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model - ScienceDirect A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0142961221006153-gr4.jpg)
A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model - ScienceDirect
![Fernand Bteich on X: "13/ Typical induction regimen is 7+3. Total is 7 days with 3 days of overlap. 7 days of cytarabine infusion. 3 days of anthracycline infusion (daunorubicin or idarubicin). Fernand Bteich on X: "13/ Typical induction regimen is 7+3. Total is 7 days with 3 days of overlap. 7 days of cytarabine infusion. 3 days of anthracycline infusion (daunorubicin or idarubicin).](https://pbs.twimg.com/media/EpFi8rbXMAAhFe_.jpg)
Fernand Bteich on X: "13/ Typical induction regimen is 7+3. Total is 7 days with 3 days of overlap. 7 days of cytarabine infusion. 3 days of anthracycline infusion (daunorubicin or idarubicin).
Therapy protocol Slika 1. Protokol terapije * daunorubicin 45 mg/m 2 or... | Download Scientific Diagram
![IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review](https://www.mdpi.com/ijms/ijms-22-04955/article_deploy/html/images/ijms-22-04955-g002.png)
IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review
![Determination of free and encapsulated cytarabine and daunorubicin in rat plasma after intravenous administration of liposomal formulation using ultra-high performance liquid chromatography tandem mass spectrometry - ScienceDirect Determination of free and encapsulated cytarabine and daunorubicin in rat plasma after intravenous administration of liposomal formulation using ultra-high performance liquid chromatography tandem mass spectrometry - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1570023222001799-ga1.jpg)
Determination of free and encapsulated cytarabine and daunorubicin in rat plasma after intravenous administration of liposomal formulation using ultra-high performance liquid chromatography tandem mass spectrometry - ScienceDirect
![Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells | Scientific Reports Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsrep41950/MediaObjects/41598_2017_Article_BFsrep41950_Fig1_HTML.jpg)
Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells | Scientific Reports
![VALIDATED STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF DAUNORUBICIN AND CYTARABINE IN BULK AND ITS PHARMACEUTICAL DOSAGE FORM | Semantic Scholar VALIDATED STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF DAUNORUBICIN AND CYTARABINE IN BULK AND ITS PHARMACEUTICAL DOSAGE FORM | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ee692bf8a8fc38d0afa7caaa3c44728d57f19280/4-Figure3-1.png)
VALIDATED STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF DAUNORUBICIN AND CYTARABINE IN BULK AND ITS PHARMACEUTICAL DOSAGE FORM | Semantic Scholar
![Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study | Leukemia Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study | Leukemia](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsj.leu.2403336/MediaObjects/41375_2004_Article_BF2403336_Fig1_HTML.gif)
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study | Leukemia
![VALIDATED STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF DAUNORUBICIN AND CYTARABINE IN BULK AND ITS PHARMACEUTICAL DOSAGE FORM | Semantic Scholar VALIDATED STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF DAUNORUBICIN AND CYTARABINE IN BULK AND ITS PHARMACEUTICAL DOSAGE FORM | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ee692bf8a8fc38d0afa7caaa3c44728d57f19280/2-Figure1-1.png)
VALIDATED STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF DAUNORUBICIN AND CYTARABINE IN BULK AND ITS PHARMACEUTICAL DOSAGE FORM | Semantic Scholar
![Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419346460-gr3.jpg)
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect
![Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - Annals of Oncology Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/5ff56d0d-a90a-4910-98e0-5d7df689dac5/gr1.jpg)
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - Annals of Oncology
![The effect of varying the buffer pHs to (a) 5.4, (b) 5.8, and (c) 6.2.... | Download Scientific Diagram The effect of varying the buffer pHs to (a) 5.4, (b) 5.8, and (c) 6.2.... | Download Scientific Diagram](https://www.researchgate.net/profile/Siew-Gan/publication/45183543/figure/fig4/AS:667822543888384@1536232710057/The-effect-of-varying-the-buffer-pHs-to-a-54-b-58-and-c-62-Ara-C-DOX-and.png)
The effect of varying the buffer pHs to (a) 5.4, (b) 5.8, and (c) 6.2.... | Download Scientific Diagram
![Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies | Leukemia Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2012.1/MediaObjects/41375_2012_Article_BFleu20121_Fig1_HTML.jpg)